IWF: Don't let government 'help' rising health care costs

Friday, February 16, 2018
 | 
Chris Woodward (OneNewsNow.com)

stethoscope and cashA health care analyst says no one should be surprised by rising health care costs but warns about manipulating a system that is working overall. 

The Department of Health and Human Services (HHS) projects health care spending will rise an average of 5.5 percent annually or one percentage point faster than economic growth, thereby squeezing public insurance programs and private employers who provide coverage.

HHS cites an aging population as one driver, along with an increase in health care services and prescription drugs.

"We've really done nothing to try to contain the cost of health care," responds Hadley Heath Manning, director of policy at Independent Women's Forum (IWF).

Manning

She recalls that the Affordable Care Act was supposedly aimed at reducing health care costs but it did so depending on the health insurance market.

"So there are a lot of subsidies in the ACA for health insurance, and there is a Medicaid expansion," she observes, "but those policy provisions don't really touch on the actual health care services that people consume and don't put the right incentives into place to hold prices down."

When it comes to prescription drugs, liberals and conservatives agree something needs to be done about the cost but are divided on how to solve the problem.

Liberals, for example, want price controls.

doctor writing prescription"The cost of drugs is not something we're going to solve via price controls," responds Manning. "Other countries have tried that and instead the result is usually drug shortages and more difficult access to the drugs that people need - a slow-down in innovation. And those foreign price controls actually come back to haunt American customers because we end up paying more because of foreign price controls."

Pointing to the HHS report, Manning says there are very steep increases in the cost of prescription drugs due to the fact that the cost of bringing those drugs to market has increased over past years.

"The cost of research and development (R&D) is so high," she says, "because the cost of FDA trials is so high, and because drugs go through a period where they are patented and there is market exclusivity for the creators of new drugs where there is no market competition."

That allows the initial investors to recoup their up-front costs for research and development, she observes, but those drug prices drop when the patent expires.

"So some of this is just inherent to our system that protects intellectual property," Manning says. " But there is also other things that we can do to make it easier to fast-track the development and testing of new drugs that come to market, because these are obviously innovations we want to see."

Consider Supporting Us?

The staff at Onenewsnow.com strives daily to bring you news from a biblical perspective. If you benefit from this platform and want others to know about it please consider a generous gift today.

MAKE A DONATION

Comments

We moderate all reader comments, usually within 24 hours of posting (longer on weekends). Please limit your comment to 300 words or less and ensure it addresses the article - NOT another reader's comments. Comments that contain a link (URL), an inordinate number of words in ALL CAPS, rude remarks directed at other readers, or profanity/vulgarity will not be approved. More details

SIGN UP FOR OUR DAILY NEWSBRIEF

SUBSCRIBE

VOTE IN OUR POLL

When faced with choosing 'the lesser of two evils' between candidates, what's your determining factor when voting?

CAST YOUR VOTE

GET PUSH NOTIFICATIONS

SUBSCRIBE

LATEST AP HEADLINES

Pence aide out of running to be Trump's next chief of staff
Winter storm causes icy roads across swath of South
Macron to break silence, address French nation amid protests
Amazon touted as big win for NY, but math is more complex
UK's May: 'Uncharted waters' if lawmakers reject Brexit deal
In Gaza protests, Israeli troops aim for the legs
Paris cleans up after latest riot; pressure builds on Macron

LATEST FROM THE WEB

Corsi sues Mueller over alleged grand jury leaks, seeks $350M in damages: report
Judge orders new fact-finding in Clinton email scandal, hits Hillary with scathing critique
Supreme Court expert: Politics strongly impacts judges' decisions
Comey says Trump wasn't among 'four Americans' targeted in FBI probe
Former FBI director James Comey says he doesn't know or can't recall in response to many lawmaker questions, transcript shows

CARTOON OF THE DAY

Cartoon of the Day

REASON & COMPANY

NEXT STORY
No longer on defensive, Trump plays offense at CPAC

Donald Trump mean decisiveOne conservative political scientist believes that it will be extraordinarily difficult for Republicans or Democrats to oppose President Donald Trump's initiatives following his speech before a conservative gathering near Washington, D.C.